Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
PBAXU Phoenix Biotech Acquisition Corp.
10.320+0.020+0.19%
Trading Session
02/02 11:22 ET
High
10.350
Open
10.350
Turnover
14.47K
Low
10.320
Pre Close
10.300
Volume
1.40K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) Sees Large Decrease in Short Interest
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX – Get Rating) was the recipient of a large drop in short interest in the month of December. As of December 30th, there was short interest totalling 9,10
Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement
SEATTLE, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Intrinsic Medicine, Inc. (Intrinsic), a therapeutics company leveraging human milk biology to transform Gut-Brain Axis (GBA) and inflammatory disorders, and Phoenix Biotech
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXW) Sees Large Increase in Short Interest
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXW – Get Rating) was the target of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU) Shares Acquired by Wolverine Asset Management LLC
Wolverine Asset Management LLC lifted its position in shares of Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU – Get Rating) by 126.6% in the 2nd quarter, according to its most recent filing with t
Press Release: Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Leveraging Human Milk Biology to Treat Gut-Brain Axis Disorders
Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Leveraging Human Milk Biology to Treat Gut-Brain Axis Disorders -- Intrinsic's pipeline
Short Interest in Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXW) Declines By 52.6%
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXW – Get Rating) was the target of a significant drop in short interest during the month of October. As of October 15th, there was short interest totallin
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) Short Interest Down 71.6% in October
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX – Get Rating) was the recipient of a large decline in short interest in the month of October. As of October 15th, there was short interest totalling 2,7
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) Is Favoured by Institutional Owners Who Hold 63% of the Company
If you want to know who really controls Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXW) Short Interest Update
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXW – Get Rating) was the target of a large drop in short interest in the month of August. As of August 15th, there was short interest totalling 2,400 shar
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) Short Interest Up 40.4% in July
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX – Get Rating) was the recipient of a large increase in short interest during the month of July. As of July 31st, there was short interest totalling 7,30
Company Overview
More
Phoenix Biotech Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 7, 2021 and is headquartered in Oakland, CA.
CEO： Mr. Chris Ehrlich
Market： NASDAQ
Listing Date： 11/30/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet